Articles producció científica> Enginyeria Electrònica, Elèctrica i Automàtica

Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder

  • Dades identificatives

    Identificador: imarina:9216318
    Autors:
    Laguna, AriadnaXicoy, HelenaTolosa, EduardoSerradell, MonicaVilas, DoloresGaig, CarlesFernandez, ManelYanes, OscarSantamaria, JoanAmigo, NuriaIranzo, AlexVila, Miquel
    Resum:
    Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson's disease (PD)) or dementia (dementia with Lewy bodies (DLB)). To provide insights into the underlying pathogenic mechanisms, the lipoprotein and protein glycosylation profile of 82 iRBD patients, collected before and/or after their conversion to an overt LTS, and 29 matched control serum samples were assessed by nuclear magnetic resonance (NMR) spectroscopy. Data were statistically analyzed to identify altered metabolites and construct predictive models. Univariant analysis detected no differences between iRBD patients with an LTS compared to controls. However, significant differences were found when the analysis distinguished between iRBD patients that manifested initially predominant parkinsonism (pre-PD) or dementia (pre-DLB). Significant differences were also found in the analysis of paired iRBD samples pre- and post-LTS diagnosis. Predictive models were built and distinguished between controls and pre-DLB patients, and between pre-DLB and pre-PD patients. This allowed a prediction of the possible future clinical outcome of iRBD patients. We provide evidence of altered lipoprotein and glycosylation profiles in subgroups of iRBD patients. Our results indicate that metabolic alterations and inflammation are involved in iRBD pathophysiology, and suggest biological differences underlying the progression of LTS in iRBD patients. Our data also indicate that profiling of serum samples by NMR may be a useful tool for identifying short-term high-risk iRBD patients for conversion to parkinsonism or dementia.
  • Altres:

    Autor segons l'article: Laguna, Ariadna; Xicoy, Helena; Tolosa, Eduardo; Serradell, Monica; Vilas, Dolores; Gaig, Carles; Fernandez, Manel; Yanes, Oscar; Santamaria, Joan; Amigo, Nuria; Iranzo, Alex; Vila, Miquel
    Departament: Enginyeria Electrònica, Elèctrica i Automàtica
    Autor/s de la URV: Yanes Torrado, Óscar
    Paraules clau: Very low density lipoprotein Triacylglycerol Tobacco use Synucleinopathy Sensitivity and specificity Risk assessment Risk Rem sleep Receiver operating characteristic Protein glycosylation Protein fingerprinting Protein Prevalence Predictive value Prediction Pathophysiology Parkinsonism Parasomnia Outcome assessment Obesity Nuclear magnetic resonance spectroscopy Nuclear magnetic resonance Neurologic disease Neurodegeneration Metabolism Markers Management Male Major clinical study Low density lipoprotein Lipoprotein Intermediate density lipoprotein Inflammation Hypertension Human High density lipoprotein Female False discovery rate Dyslipidemia Disease exacerbation Disease Diagnostic test accuracy study Diagnosis Diabetes mellitus Dementia Data analysis Controlled study Comorbidity Cohort analysis Clinical outcome Cholesterol Blood sampling Biological marker Behavior disorder Article Area under the curve Aged
    Resum: Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) is a prodromal stage of Lewy-type synucleinopathies (LTS), which can present either with an initial predominant parkinsonism (Parkinson's disease (PD)) or dementia (dementia with Lewy bodies (DLB)). To provide insights into the underlying pathogenic mechanisms, the lipoprotein and protein glycosylation profile of 82 iRBD patients, collected before and/or after their conversion to an overt LTS, and 29 matched control serum samples were assessed by nuclear magnetic resonance (NMR) spectroscopy. Data were statistically analyzed to identify altered metabolites and construct predictive models. Univariant analysis detected no differences between iRBD patients with an LTS compared to controls. However, significant differences were found when the analysis distinguished between iRBD patients that manifested initially predominant parkinsonism (pre-PD) or dementia (pre-DLB). Significant differences were also found in the analysis of paired iRBD samples pre- and post-LTS diagnosis. Predictive models were built and distinguished between controls and pre-DLB patients, and between pre-DLB and pre-PD patients. This allowed a prediction of the possible future clinical outcome of iRBD patients. We provide evidence of altered lipoprotein and glycosylation profiles in subgroups of iRBD patients. Our results indicate that metabolic alterations and inflammation are involved in iRBD pathophysiology, and suggest biological differences underlying the progression of LTS in iRBD patients. Our data also indicate that profiling of serum samples by NMR may be a useful tool for identifying short-term high-risk iRBD patients for conversion to parkinsonism or dementia.
    Àrees temàtiques: Neurosciences Neurology (clinical) Neurology Cellular and molecular neuroscience
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: oscar.yanes@urv.cat
    Identificador de l'autor: 0000-0003-3695-7157
    Data d'alta del registre: 2024-10-12
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://www.nature.com/articles/s41531-021-00184-9
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Npj Parkinsons Dis. 7 (1): 40-
    Referència de l'ítem segons les normes APA: Laguna, Ariadna; Xicoy, Helena; Tolosa, Eduardo; Serradell, Monica; Vilas, Dolores; Gaig, Carles; Fernandez, Manel; Yanes, Oscar; Santamaria, Joan; Am (2021). Serum metabolic biomarkers for synucleinopathy conversion in isolated REM sleep behavior disorder. Npj Parkinsons Dis, 7(1), 40-. DOI: 10.1038/s41531-021-00184-9
    DOI de l'article: 10.1038/s41531-021-00184-9
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2021
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Cellular and Molecular Neuroscience,Neurology,Neurology (Clinical),Neurosciences
    Very low density lipoprotein
    Triacylglycerol
    Tobacco use
    Synucleinopathy
    Sensitivity and specificity
    Risk assessment
    Risk
    Rem sleep
    Receiver operating characteristic
    Protein glycosylation
    Protein fingerprinting
    Protein
    Prevalence
    Predictive value
    Prediction
    Pathophysiology
    Parkinsonism
    Parasomnia
    Outcome assessment
    Obesity
    Nuclear magnetic resonance spectroscopy
    Nuclear magnetic resonance
    Neurologic disease
    Neurodegeneration
    Metabolism
    Markers
    Management
    Male
    Major clinical study
    Low density lipoprotein
    Lipoprotein
    Intermediate density lipoprotein
    Inflammation
    Hypertension
    Human
    High density lipoprotein
    Female
    False discovery rate
    Dyslipidemia
    Disease exacerbation
    Disease
    Diagnostic test accuracy study
    Diagnosis
    Diabetes mellitus
    Dementia
    Data analysis
    Controlled study
    Comorbidity
    Cohort analysis
    Clinical outcome
    Cholesterol
    Blood sampling
    Biological marker
    Behavior disorder
    Article
    Area under the curve
    Aged
    Neurosciences
    Neurology (clinical)
    Neurology
    Cellular and molecular neuroscience
  • Documents:

  • Cerca a google

    Search to google scholar